Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Recruitment status was Active, not recruiting
RATIONALE: Studying how older women make treatment decisions and how these decisions affect the outcome of treatment may help doctors plan more effective treatments and improve patient quality of life.
PURPOSE: This clinical trial is studying how a patient's treatment preferences and decisions about chemotherapy affect the outcome of treatment in older women with newly diagnosed breast cancer.
Psychosocial Effects of Cancer and Its Treatment
Procedure: psychosocial assessment and care
Procedure: quality-of-life assessment
|Official Title:||Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer|
|Study Start Date:||August 2003|
|Estimated Primary Completion Date:||July 2005 (Final data collection date for primary outcome measure)|
- Determine the relationship between preferences and chemotherapy decisions in women age 65 and over with operable, newly diagnosed breast cancer.
- Determine how factors that could be targets for intervention affect the relationship between preferences and chemotherapy decisions in these patients.
- Determine the relationships between preference-based chemotherapy decisions, quality of life, and satisfaction with treatment decisions in these patients.
- Determine the disease-free survival and competing causes of mortality of these patients.
- Determine the types of physician providers who care for older breast cancer survivors after initial cancer treatment is completed and explore how women decide about which physicians to see.
- Measure quality indicators for the survivorship phase of care and evaluate if quality varies by type of physician provider model.
- Determine if long-term patient-reported satisfaction varies as a function of physician model for providing follow-up care post-treatment.
- Determine whether physician-patient communication and coordination of care after treatment ends mediate follow-up quality and outcomes post-treatment.
OUTLINE: This is a cohort study.
Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.
Patients are followed annually for at least 5 years.
PROJECTED ACCRUAL: A total of 1,296 patients will be accrued for this study within 18-24 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00068328
Show 85 Study Locations
|Study Chair:||Jeanne Mandelblatt, MD, MPH||Lombardi Cancer Research Center|
|Investigator:||Alice B. Kornblith, PhD||Dana-Farber Cancer Institute|
|Investigator:||Hyman B. Muss, MD||University of Vermont|
|Investigator:||Stephen B. Edge, MD||Roswell Park Cancer Institute|